Healthcare ❯ Infectious Diseases
Variants Symptoms Patient Care Vaccine Safety Adenovirus Vaccination Efficacy Testing Procedures Comorbidities Patient Management Testing and Screening Statistics Long COVID Diagnostic Solutions Sars-CoV-2 Heart Conditions Vaccine Distribution Vaccination Recommendations Viral Infections
The agreement offers $76 in cash per share plus up to $3 tied to breast health revenue, with closing targeted in the first half of 2026 pending all required approvals.